Back

Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: a meta-analysis of randomized controlled trials

19 May 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Diverse pharmacological progress in heart failure Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Renzo Laborante

South General Hospital, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail
Real-world use and effectiveness of patiromer among patients with heart failure at high risk of hyperkalaemia: insights from the CARE-HK in HF registry
Doctor A. Sauer (Kansas City, US)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose co-transporter-2 inhibitors: prognostic benefit in real-world, elderly, comorbid HFmrEF and HFpEF patients
Mrs S. Valdivielso (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Diuretic resistance and the efficacy of hydrochlorothiazide in acute decompensated heart failure: a post-hoc analysis of the CLOROTIC Trial
Doctor A. Pandey (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Impact of l-arginine supplementation on quality of life in patients with heart failure: a meta-analysis of randomized controlled trials
Doctor A. Alvez (Quezon City, PH)
Abstract Slides Video
Presentation thumbnail
Serum digoxin concentrations in patients with heart failure: a post-hoc analysis of the BIOSTAT-CHF study
Mr D. Baron (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Diverse pharmacological progress in heart failure

The Event

Event poster

Heart Failure 2025

19 May 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Timing matters: clinical outcomes of early sodium-glucose cotransporter-2 inhibitor initiation in acute heart failure
thumbnail
Congress Presentation
Impact of LVEF and de novo heart failure on outcomes of SGLT2 inhibitor therapy initiated during acute heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources